71 completed, 11 active not recruiting, 5 terminated, 4 recruiting. 52 Phase 1, 48 Phase 2, 7 Phase 3, 4 Not applicable, 1 Early Phase 1.
Follow Adjuvants, Pharmaceutic: new trials by email Literature Review of Adjuvants, Pharmaceutic trials Research Report on Adjuvants, Pharmaceutic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab - Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm | Phase 2 | Not yet recruiting | VA Office of Research and Development | 30 | 2026-12-01 | 2026-10-06 |
| Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis B TVAX-028, Adjuvant - HBV Infection | Phase 1 | Not yet recruiting | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | 32 | 2026-05-31 | 2026-06-29 |
| Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant) - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Recruiting | Ab&B Bio-tech Co., Ltd.JS | 470 | 2026-05-14 | 2026-05-27 |
| Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older Subunit Influenza Vaccine (Adjuvant), MF59, 0.9% sodium chloride injection (normal saline) - Influenza, Influenza Vaccine | Phase 1 | Active not recruiting | Ab&B Bio-tech Co., Ltd.JS | 80 | 2025-11-13 | 2026-02-19 |
| Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older Quadrivalent Subunit Influenza Vaccine (Adjuvant), MF59, 0.9% sodium chloride injection (normal saline) - Influenza, Influenza Vaccine | Phase 1 | Active not recruiting | Ab&B Bio-tech Co., Ltd.JS | 80 | 2025-11-13 | 2026-02-19 |
| Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation, RABIVAX-S - Prevention of Malaria Transmission and Clinical Malaria | Phase 2 | Active not recruiting | Serum Institute of India Pvt. Ltd. | 1200 | 2025-08-22 | 2026-07-08 |
| Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma Neoadjuvant Chemotherapy (NACT), Neoadjuvant and maintenance Tislelizumab, Concurrent chemo-radiotherapy (CCRT) - Laryngeal Carcinoma, Hypopharyngeal Carcinoma | Phase 3 | Not yet recruiting | Fudan University | 168 | 2025-04-28 | 2025-05-08 |
| A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals Recombinant herpes zoster vaccine with low-dose adjuvant, Recombinant herpes zoster vaccine with high-dose adjuvant, Low-dose adjuvant - Herpes Zoster (HZ) | Phase 1 / Phase 2 | Recruiting | Shanghai Institute Of Biological Products | 645 | 2025-04-04 | 2026-01-07 |
| Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine - Lung Neoplasm Malignant | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2025-03-20 | 2026-10-13 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health 426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant - HIV | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 42 | 2025-03-17 | 2025-09-25 |
| Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant - Cancer | Phase 2 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-01 | 2025-12-01 | |
| Postoperative Analgesic Efficacy of Adjuvant Quadratus Lumborum Block in Open Inguinal Hernia Surgery ANTERİOR QUADRATUS LUMBORUM BLOCK, ANTERİOR QUADRATUS LUMBORUM BLOCK WİTH ADJUVANT - Pain, Postoperative | Not applicable | Completed | Gaziosmanpasa Research and Education Hospital | 67 | 2024-11-01 | 2025-08-28 |
| RSV Vaccine in Transplant Recipients Adjuvant, non-live RSV vaccine - Vaccine Response Impaired, Respiratory Syncytial Virus Infections | Phase 3 | Active not recruiting | University Health Network, Toronto | 100 | 2024-10-01 | 2026-05-01 |
| Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM), : Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) - HIV | Early Phase 1 | Withdrawn | International AIDS Vaccine Initiative | 2024-08-27 | 2025-03-14 | |
| A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults LYB005 low dose without adjuvant, LYB005 middle dose without adjuvant, LYB005 high dose without adjuvant - Respiratory Syncytial Virus (RSV), RSV Infection | Phase 1 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 84 | 2024-07-31 | 2025-03-13 |
| Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA) - H7N9 Influenza | Phase 1 | Completed | Vaxxas Pty Ltd | 267 | 2024-07-31 | 2026-03-27 |
| The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies 426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum - Chronic HIV Infection | Phase 1 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 35 | 2024-01-03 | 2026-01-14 |
| Evaluation of Effectivity of Quadratus Lumborum Blocks With Adjuvant Adjuvant-free Quadratus lumborum block, Quadratus lumborum block III with Adjuvant - Postoperative Pain Management, Postoperative Pain | Not applicable | Completed | Gaziosmanpasa Research and Education Hospital | 83 | 2023-09-01 | 2024-10-29 |
| Evaluation of Adjuvant Use in Selective Trunk Block Dexamethasone, kontrol group - Analgesia, Nerve Blocks | Not applicable | Completed | Gaziosmanpasa Research and Education Hospital | 71 | 2023-04-28 | 2024-09-24 |
| Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) Tislelizumab + Dasatinib + Quercetin (neoadjuvant), surgery, Tislelizumab + Dasatinib + Quercetin (adjuvant) - Head and Neck Squamous Cell Carcinomas | Phase 2 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 24 | 2023-02-05 | 2024-09-19 |
Showing 20 of 103. Sign in to see all of them.
Influenza, Human (13) · Carcinoma, Non-Small-Cell Lung (6) · Enterovirus Infections (4) · Herpes Simplex (4) · Pain, Postoperative (4) · Respiratory Syncytial Virus Infections (4) · Squamous Cell Carcinoma of Head and Neck (4) · Tuberculosis (4) · Lung Neoplasms (3) · Parkinson Disease (3) · Agnosia (2) · COVID-19 (2) · Carcinoma, Hepatocellular (2) · Clostridium Infections (2) · Diarrhea (2)
Novavax (6) · Sanofi Pasteur, a Sanofi Company (6) · Genocea Biosciences, Inc. (5) · Medigen Vaccine Biologics Corp. (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Affiris AG (4) · Ab&B Bio-tech Co., Ltd.JS (3) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (3) · BioNTech US Inc. (3) · Gaziosmanpasa Research and Education Hospital (3) · Enimmune Corporation (2) · Fudan University (2) · Immune Targeting Systems Ltd (2) · Shiga University (2) · Sinovac Biotech Co., Ltd (2)
United States (41) · China (18) · Taiwan (7) · Australia (4) · France (4) · Spain (4) · Turkey (Türkiye) (4) · Belgium (3) · Canada (3) · Netherlands (3) · Austria (2) · Chile (2) · Egypt (2) · Finland (2) · Germany (2)
D. Nigel Thomas, Ph.D. (3) · Mark DeMario, MD (3) · Szu-Min Hsieh, MD (3) · Tzou-Yien Lin, MD (3) · Nigel Thomas, Ph.D (2) · Yan-pin Li, MD (2) · Yeqing Tong, Doctor (2) · Aleix Prat, MD (1) · Almudena Zapatero, MD PhD, IP (1) · Christina Chang, M.D (1)
PMID 36560565, PMID 16170164, PMID 20979455, PMID 21256189, PMID 22426371, PMID 23352749, PMID 24732325, PMID 25158710, PMID 25444714, PMID 25702876, PMID 25987569, PMID 26154128, PMID 26259809, PMID 26311728, PMID 27013431, PMID 27581434, PMID 27598804, PMID 28081133, PMID 28413427, PMID 28445469, PMID 28668573, PMID 30302282, PMID 30941670, PMID 31070691, PMID 31103365, PMID 31399275, PMID 31537446, PMID 31621801, PMID 32444629, PMID 32534628, PMID 32665297, PMID 32726529, PMID 32882100, PMID 32955177, PMID 33064988, PMID 33186516, PMID 33294862, PMID 33887209, PMID 33969434, PMID 34174187, PMID 34655522, PMID 35035955, PMID 35039439, PMID 35427469, PMID 35950709, PMID 36256646, PMID 36348617, PMID 36403700, PMID 36526640, PMID 36679862
2008 (2), 2009 (2), 2014 (2), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2023 (1), R01GM097531 (1), U19AI090023 (1)